Drug intelligence / Profile preview

61Cu-NU101

Development stage: Phase 2
Lead developer: Nuclidium
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

61Cu-NU101 (also known as 61Cu-noDAGa-PSMA I&T) is an investigational radiopharmaceutical diagnostic imaging agent developed by Hoag Memorial Hospital Presbyterian for the detection of prostate cancer metastases. It consists of the positron-emitting radioisotope copper-61 (61Cu) complexed with the chelator noDAGa and conjugated to the PSMA I&T ligand. This agent targets Prostate-Specific Membrane Antigen (PSMA), a protein highly expressed on the surface of prostate cancer cells. By binding to PSMA, 61Cu-NU101 allows for high-resolution Positron Emission Tomography (PET) imaging of primary and metastatic prostate cancer lesions. The use of 61Cu, which has a half-life of approximately 3.3 hours, may offer logistical advantages over other PSMA-targeted tracers like 68Ga-PSMA-11 or 18F-DCFPyL (Pylarify) by allowing for centralized production and longer imaging windows. It is currently being evaluated in Phase 2 clinical trials to compare its diagnostic performance against FDA-approved PSMA PET agents.

Other names: 61Cu-noDAGa-PSMA I&T

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 61Cu-NU101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 61Cu-NU101.

Explore the full profile